Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822925 · ClinicalTrials.gov registry record · Phase 2
Study of DA-9801 to Treat Diabetic Neuropathy
A Phase 2 study of Diabetic Neuropathy, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 14
- Study locations
NCT01822925 is a Phase 2 study of Diabetic Neuropathy that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 128 participants, below the 168-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (24% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT01822925, a Phase 2 study of Diabetic Neuropathy, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 14
- Study locations
Study Summary
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DA-9801 300mg
- DRUG DA-9801 600mg
- DRUG DA-9801 900mg
Study Locations (14)
Texas
- KRK Research - Dallas
- North Texas Endocrine Center - Dallas
- Houston Foot & Ankle Care - Houston
California
- Center for United Research, Inc. - Lakewood
- Diablo Clinical Research - Walnut Creek
Florida
- PAB Clinical Research - Brandon
- Metabolic Research Institute, Inc. - West Palm Beach
Connecticut
- Clinical Research Consulting, LLC - Milford
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Novex Clinical Research, Inc. - New Bedford
New York
- Albany Medical Center - Albany
South Carolina
- Coastal Carolina Research Center - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822925
The ClinicalTrials.gov registry entry for NCT01822925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 8 other Diabetic Neuropathy trials with a reported enrollment target (24% lower). The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Neuropathy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01822925 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01822925 about?
NCT01822925 is a clinical study titled "Study of DA-9801 to Treat Diabetic Neuropathy". To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
What is the current status of trial NCT01822925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2013-11. Estimated completion is 2015-01.
What conditions does trial NCT01822925 study?
This clinical trial studies the following conditions: Diabetic Neuropathy.
What interventions are being tested in trial NCT01822925?
The interventions under investigation include: Placebo (DRUG), DA-9801 300mg (DRUG), DA-9801 600mg (DRUG), DA-9801 900mg (DRUG).
Who is sponsoring clinical trial NCT01822925?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01822925 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
The Effect of Ruboxistaurin on Small Fiber Function
COMPLETED · Phase 2
-
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.